Abstract
Many epithelial neoplasms can be analyzed by flow cytometry (FC), particularly from serous cavity effusion samples, using EpCAM, a cell adhesion molecule expressed on most normal epithelial cells and expressed at a higher level in most epithelial neoplasms. A simple 3-color flow cytometric panel can provide a high sensitivity and specificity compared to cytomorphology. FC provides more rapid immunophenotyping than conventional immunohistochemical staining, can identify rare malignant cells that could be missed by a cytological exam alone, and can be utilized to evaluate limited samples such as cerebrospinal fluid or fine-needle aspiration samples. Flow cytometric analysis for epithelial antigens can be combined with DNA ploidy analysis or assessment of the nucleus-to-cytoplasm ratio. Panels of flow cytometric markers are useful for the assessment of pediatric nonhematopoietic neoplasms, including neuroblastomas, primitive neuroectodermal tumors, Wilms' tumor, rhabdomyosarcomas, germ cell tumors, and hemangiopericytomas, as well as small-round-blue-cell tumors in adults, including small-cell carcinomas.
References
1.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, International Agency for Research on Cancer, 2008.
2.
Wood BL: Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom 2016;90:47-53.
3.
Pillai V, Cibas ES, Dorfman DM: A simplified flow cytometric immunophenotyping procedure for the diagnosis of effusions caused by epithelial malignancies. Am J Clin Pathol 2013;139:672-681.
4.
Davidson B, Dong HP, Holth A, Berner A, Risberg B: Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. Diagn Cytopathol 2007;35:568-578.
5.
Acosta M, Pereira J, Arroz M: Screening of carcinoma metastasis by flow cytometry: a study of 238 cases. Cytometry B Clin Cytom 2016;90:289-294.
6.
Risberg B, Davidson B, Dong HP, Nesland JM, Berner A: Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings. J Clin Pathol 2000;53:513-517.
7.
Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO: Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-446.
8.
Patriarca C, Macchi RM, Marschner AK, Mellstedt H: Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012;38:68-75.
9.
Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S: Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-128.
10.
Motherby H Nadjari B, Friegel P, Kohaus J, Ramp U, Bocking A: Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999;20:350-357.
11.
Kentrou NA, Tsagarakis NK, Tzanetou K, Damala M, Papadimitriou KA, Skoumi D, Stratigaki A, Anagnostopoulos NI, Malamou-Lada E, Athanassiadou P, Paterakis G: An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions. Cytometry B Clin Cytom 2011;80:324-334.
12.
Sayed DM, el-Attar MM, Hussein AA: Evaluation of flow cytometric immunophenotyping and DNA analysis for detection of malignant cells in serosal cavity fluids. Diagn Cytopathol 2009;37:498-504.
13.
Krishan A, Ganjei-Azar P, Hamelik R, Sharma D, Reis I, Nadji M: Flow immunocytochemistry of marker expression in cells from body cavity fluids. Cytometry A 2010;77:132-143.
14.
Roca E, Lacroix R, Judicone C, Laroumagne S, Robert S, Cointe S, Muller A, Kaspi E, Roll P, Brisson AR, Tantucci C, Astoul P, Dignat-George F: Detection of EpCAM-positive microparticles in pleural fluid: a new approach to mini-invasively identify patients with malignant pleural effusions. Oncotarget 2016;7:3357-3366.
15.
Lonardi S, Manera C, Marucci R, Santoro A, Lorenzi L, Facchetti F: Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol 2011;39:313-317.
16.
Fellegara G, Carcangiu ML, Rosai J: Benign epithelial inclusions in axillary lymph nodes: report of 18 cases and review of the literature. Am J Surg Pathol 2011;35:1123-1133.
17.
Kim HS, Yoon G, Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS, Song SY: Mesothelial cell inclusions in pelvic and para-aortic lymph nodes: a clinicopathologic analysis. Int J Clin Exp Pathol 2015;8:5318-5326.
18.
Danielsen HE, Pradhan M, Novelli M: Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol 2016;13:291-304.
19.
Darzynkiewicz Z, Halicka HD, Zhao H: Analysis of cellular DNA content by flow and laser scanning cytometry. Adv Exp Med Biol 2010;676:137-147.
20.
Han X, Ping B, Morita M, Ebi R, Inoue J, Tanaka Y, Chen Y, Wan X, Yang W, Chang B, Wu X: A novel highly sensitive and specific flow cytometry system for cervical cancer screening. Gynecol Oncol 2015;139:52-58.
21.
Tsikouras P, Tsagias N, Pinidis P, Csorba R, Vrachnis N, Dafopoulos A, Bouchlarioutou S, Liberis A, Teichmann AT, von Tempelhoff GF: The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Arch Gynecol Obstet 2013;288:581-585.
22.
English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonassoli E, Chatterjee S, Ratner E, Silasi D-A, Azodi M, Schwartz PE, Rutherford TJ, Santin AD: Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2015;121:403-412.
23.
Chang A, Benda PM, Wood BL, Kussick SJ: Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry. Am J Clin Pathol 2003;119:643-655.
24.
Ferreira-Facio CS, Milito C, Botafogo V, Fontana M, Thiago LS, Olivera E, da Rocha-Filho AS, Werneck F, Forny DN, Dekermacher S, de Azambuja AP, Ferman SE, de Faria PAS, Land MGP, Orfao A, Costa ES: Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer. PLoS One 2013;8:e55534.
25.
Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD: Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998;82:733-739.
26.
de Graaf MT, de Jongste AHC, Kraan J, Boonstra JG, Sillevis Smitt PAE, Gratma JW: Flow cytometric characterization of cerebrospinal fluid cells. Cytometry B Clin Cytom 2011;80:271-281.
27.
French CA, Dorfman DM, Shaheen G, Cibas ES: Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 2000;23:369-374.
28.
Milojkovic Kerklaan B, Plum D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JHM, Brandsma D: EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro Oncol 2016;18:855-862.
29.
Subira D, Serrano C, Gonzalo R, Illan J, Pardo J, Martinez-Garcia M, Millastre E, Aparisi F, Navarro M, Domine M, Gil-Bazo I, Perez Segura P, Gil M, Bruna J: Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro Oncol 2012;14:43-52.
30.
Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M: Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 2000;13:988-993.
31.
Beiske K, Ambros PF, Burchill SA, Cheung IY, Swerts K: Detecting minimal residual disease in neuroblastoma patients - the present state of the art. Cancer Lett 2005;228:229-240.
32.
Morandi F, Corrias MV, Pistoia V: Evaluation of bone marrow as a metastatic site of human neuroblastoma. Ann NY Acad Sci 2015;1335:23-31.
33.
Cai JY, Pan C, Tang Y-J: Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration. Am J Clin Oncol 2012;35:275-278.
34.
Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson ADJ, Matthay KK: Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009;100:1627-1637.
35.
Ifversen M, Kagedal B, Christensen, L, Rechnitzer C, Petersen B, Heilmann C: Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol 2005;27:121-129.
36.
Leipold MD, Newell EW, Maecker HT: Multiparameter phenotyping of human PBMCs using mass cytometry. Methods Mol Biol 2015;1343:81-95.
37.
Yao Y, Liu R, Shin MS, Trentalange M, Allore H, Nassar A, Kang I, Pober JS, Montgomery RR: CyTOF supports efficient detection of immune cell subsets from small samples. J Immunol Methods 2014;415:1-5.
38.
Mair F, Hartmann FJ, Mrdjen D, Tosevski V, Krieg C, Becher B: The end of gating? An introduction to automated analysis of high dimensional cytometry data. Eur J Immunol 2016;46:34-43.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
